Takuya Tsunoda Selected Research

Colorectal Neoplasms (Colorectal Cancer)

11/2023	Recombinant Methioninase Lowers the Effective Dose of Regorafenib Against Colon-Cancer Cells: A Strategy for Widespread Clinical Use of a Toxic Drug.
9/2023	Rapid Reduction of CEA and Stable Metastasis in an NRAS-mutant Rectal-Cancer Patient Treated With FOLFIRI and Bevacizumab Combined With Oral Recombinant Methioninase and a Low-Methionine Diet Upon Metastatic Recurrence After FOLFIRI and Bevacizumab Treatment Alone.
8/2022	Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
4/2022	Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.
1/2020	Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
1/2020	Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients.
1/2020	Characterization of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers.
1/2019	Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
1/2016	Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
8/2012	In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takuya Tsunoda Research Topics

Disease

78	Neoplasms (Cancer) 05/2024 - 03/2002
17	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 03/2002
9	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024 - 10/2008
9	Testicular Neoplasms (Testicular Cancer) 01/2018 - 08/2005
8	Neoplasm Metastasis (Metastasis) 01/2024 - 06/2002
8	Stomach Neoplasms (Stomach Cancer) 12/2021 - 03/2002
7	Colonic Neoplasms (Colon Cancer) 01/2024 - 12/2004
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 02/2021
6	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 12/2008
5	Esophageal Neoplasms (Esophageal Cancer) 01/2024 - 11/2007
5	Lung Neoplasms (Lung Cancer) 01/2018 - 03/2002
4	Carcinoma (Carcinomatosis) 05/2024 - 07/2004
4	Esophageal Squamous Cell Carcinoma 04/2014 - 07/2008
2	Lobular Carcinoma 01/2024 - 12/2022
2	Breast Neoplasms (Breast Cancer) 01/2024 - 12/2022
2	Hepatocellular Carcinoma (Hepatoma) 11/2023 - 08/2005
2	Rectal Neoplasms (Rectal Cancer) 09/2023 - 08/2022
2	Obesity 01/2023 - 07/2022
2	Diarrhea 11/2022 - 03/2022
2	Disease Progression 08/2022 - 12/2021
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 07/2022 - 01/2005
2	Residual Neoplasm 02/2022 - 04/2014
2	Melanoma (Melanoma, Malignant) 02/2021 - 03/2002
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2014 - 12/2008
1	Alopecia (Baldness) 05/2024
1	Glioma (Gliomas) 12/2023
1	Triple Negative Breast Neoplasms 11/2023
1	Glioblastoma (Glioblastoma Multiforme) 01/2023
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2023

Drug/Important Bio-Agent (IBA)

30	Peptides (Polypeptides)IBA 11/2023 - 07/2003
21	EpitopesIBA 05/2018 - 07/2003
21	AntigensIBA 01/2018 - 07/2003
14	Immune Checkpoint InhibitorsIBA 01/2024 - 09/2019
12	Methionine (L-Methionine)FDA Link 05/2024 - 08/2022
12	Complementary DNA (cDNA)IBA 06/2016 - 07/2003
11	L-methionine gamma-lyaseIBA 05/2024 - 05/2022
11	Messenger RNA (mRNA)IBA 02/2022 - 03/2002
9	Biomarkers (Surrogate Marker)IBA 05/2024 - 03/2021
9	Cancer VaccinesIBA 01/2016 - 07/2003
8	Protein Subunit VaccinesIBA 11/2023 - 11/2008
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2004
6	Carrier Proteins (Binding Protein)IBA 06/2016 - 07/2003
6	Insulin-Like Growth Factor II (Somatomedin A)IBA 06/2016 - 11/2007
5	Protein Kinases (Protein Kinase)IBA 04/2014 - 11/2007
5	HLA-A*02:01 antigenIBA 10/2006 - 12/2004
4	HLA-A Antigens (HLA-A)IBA 05/2018 - 12/2004
4	VaccinesIBA 05/2018 - 12/2012
4	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 07/2015 - 06/2005
4	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 04/2014 - 10/2006
4	HLA-A24 AntigenIBA 04/2011 - 07/2004
3	regorafenibIBA 11/2023 - 01/2020
3	pembrolizumabIBA 09/2023 - 01/2022
3	NivolumabIBA 09/2023 - 05/2021
3	B7-H1 AntigenIBA 01/2023 - 02/2021
3	Carcinoembryonic AntigenIBA 12/2022 - 07/2003
3	Irinotecan (Camptosar)FDA LinkGeneric 05/2022 - 01/2021
3	EnzymesIBA 12/2021 - 08/2009
3	Gemcitabine FDA Link 07/2015 - 11/2008
3	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2014 - 10/2008
3	Cadherins (E-Cadherin)IBA 08/2012 - 10/2008
3	Insulin-Like PeptidesIBA 08/2009 - 11/2007
2	HomocysteineIBA 05/2024 - 05/2023
2	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 01/2023
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2023 - 11/2008
2	Bevacizumab (Avastin)FDA Link 09/2023 - 01/2019
2	LigandsIBA 09/2023 - 01/2023
2	AntibodiesIBA 09/2023 - 12/2021
2	Fluorouracil (Carac)FDA LinkGeneric 01/2023 - 05/2022
2	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 10/2012
2	Therapeutic UsesIBA 12/2022 - 02/2022
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2022 - 01/2016
2	Alanine Transaminase (SGPT)IBA 11/2022 - 06/2021
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2022 - 06/2021
2	Imatinib Mesylate (Gleevec)FDA Link 07/2022 - 01/2005
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 01/2019
2	Capecitabine (Xeloda)FDA Link 01/2020 - 01/2019
2	arginyl- phenylalanyl- valyl- prolyl- aspartyl- glycyl- asparagyl- arginyl- isoleucineIBA 07/2015 - 12/2012
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2014 - 08/2013
2	KinesinsIBA 08/2013 - 01/2012
2	Small Interfering RNA (siRNA)IBA 08/2006 - 08/2005
1	Volatile Fatty AcidsIBA 05/2024
1	isobutyric acidIBA 05/2024
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2024
1	Red Fluorescent ProteinIBA 01/2024
1	Green Fluorescent ProteinsIBA 01/2024
1	MethyltransferasesIBA 12/2023
1	Temozolomide (Temodar)FDA LinkGeneric 12/2023
1	Phosphates (Orthophosphate)IBA 11/2023
1	Cytotoxins (Cytolysins)IBA 05/2023
1	IsotopesIBA 01/2023
1	Deoxyglucose (2 Deoxy D glucose)IBA 01/2023

Therapy/Procedure

27	Therapeutics 05/2024 - 03/2002
25	Immunotherapy 05/2024 - 07/2003
12	Drug Therapy (Chemotherapy) 01/2024 - 02/2005
3	Lasers (Laser) 01/2024 - 03/2021
3	Aftercare (After-Treatment) 01/2024 - 09/2019
2	Oral Administration 05/2024 - 01/2023
2	Radiotherapy 09/2023 - 07/2012
1	Combination Drug Therapy (Combination Chemotherapy) 01/2024
1	Laparotomy 01/2024